Investors who held Novavax from the start of the year are up 51.2%, including dividends. That kind of gain grabs attention, especially after years where headlines swung between fresh licensing deals and worries about a shrinking COVID franchise. If you were weighing a position back in January, you faced clashing analyst views on revenue decline, regulation and partnership upside. Which of those early questions around Novavax’s narrow portfolio and licensing shift mattered most?
Novavax is not the only name tied to this theme. Zero in on 35 healthcare AI stocks and compare how each one is priced.
The Case For And Against Novavax At The Time
The shares cost US$6.72 at the start of the period, so any view on Novavax hinged on what investors thought its licensing strategy and vaccine pipeline could realistically support.
The bullish story saw a leaner, partner-led model creating value, with a Fair Value of US$12.5 that reflected the price those assumptions implied. Supporters focused on partnership income, a shift toward recurring royalties, and a future P/E assumption of 46.2x.
The more cautious narrative pointed to a narrow portfolio and regulatory pressure, with a Fair Value of US$6. Bearish investors focused on an assumed revenue decline of 54.0% and dependence on COVID and flu products.
What The Results Changed For The Novavax Thesis
The biggest development was Novavax collecting a US$125 million milestone from Sanofi once the Phase 3 flu COVID trial began. This supported the bullish focus on licensing and partner-funded work. At the same time, Q3 2026 revenue of US$68.3 million was slightly lower than Q3 2025, and the business still reported a loss, so profitability in the upbeat case remained unproven. The evidence cut both ways.
The lesson for other stocks is clear. When a story hinges on a licensing shift, track how much cash actually arrives from milestones and what happens to net margin in the filings, not just the size of the announced pipeline.
What Novavax’s Run Now Prices In
Novavax trades at US$10.78 today, after a 51.2% gain from the start of the year. The selected Narrative’s Fair Value sits below the current price, which signals that its authors see the market paying up for execution that is not yet reflected in reported results.
The argument now hinges on Matrix M licensing turning into regular royalties that support a leaner cost base. Anyone buying at today’s level is effectively assuming that partnered programs convert into timely, durable cash flows, so the question is how the highlighted revenue concentration and funding risks affect that assumption.
"The main thing that has to go right is for Novavax’s Matrix M partnerships with large pharmaceutical companies, including the COVID influenza combination programs and oncology MTAs, to convert into recurring royalties and milestone payments that support the leaner cost base."
That disagreement has a full argument behind it. → Uncover the lower Fair Value this Narrative argues for
Find Your Own Contrarian Opportunity
What if your next investment idea came before the headlines? Go straight to the companies whose prices and our estimates still disagree. Three places to start, with the names waiting behind the link.
- Company 1 - 27% below our estimate - uses recent acquisitions and evolving deposit mix to reshape lending economics.
- Company 2 - 16% below our estimate - expands overseas teahouse locations while monitoring franchise profitability and operating efficiency.
- Company 3 - 33% below our estimate - scales coconut based drinks through branded and private label partnerships despite cost pressures.
Those are three of them. See the full list of 38 companies trading below our fair value estimates →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com